Source comparison
BPC-157 Compounding Pharmacy: Comparison of Facility Types
503A Compounding Pharmacy State pharmacy board only Not required by federal law Required for sterile preparations State-dependent (typically biennial) Patient-specific prescriptions in small batches Appropriate for individualised formulations under practitione
This comparison does not assign a generated winner or score.
- 503A Compounding Pharmacy
- State pharmacy board only
- Not required by federal law
- Required for sterile preparations
- State-dependent (typically biennial)
- Patient-specific prescriptions in small batches
- Appropriate for individualised formulations under practitioner oversight. Lacks batch-level verification for research applications
- 503B Outsourcing Facility
- FDA registration + state board
- Potency, sterility, endotoxin testing mandatory on every batch
- cGMP compliance required
- FDA unannounced inspections
- Large-scale compounding for distribution without prescriptions
- Gold standard for research-grade peptides. Documented batch verification and traceable quality control
- Direct Peptide Vendor (Research Use Only)
- No FDA oversight; exempt as raw material supplier
- Voluntary only. No legal requirement
- Not required
- None
- Consumer direct sales marketed for research
- No regulatory verification of claims. Potency and contamination widely variable across vendors
- This table clarifies why source classification matters. A prescription from a licensed practitioner doesn't guarantee quality if the BPC-157 compounding pharmacy preparing it is a 503A facility without batch testing protocols. Conversely, a 503B facility operating without prescriptions provides verified product quality but doesn't involve medical oversight of the use case. Real Peptides operates as a registered supplier with testing standards that match 503B protocols. Full batch documentation provided with every order.